1 APOLLOHOSP share price target reports by brokerages below. See what is analyst's view on APOLLOHOSP share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
The company continues to deliver a healthy set of numbers on the revenues and cost fronts. The overall narrative is panning out on expected lines with sustained margin expansion and improvement in RoCE, as guided by the management at the beginning of the last fiscal. The management has reiterated a similar strategy, going ahead, with more focus on consolidation of the existing hospitals and making new hospitals profitable. The company has one of the best integrated business models in the healthcare space with a strong management pedigree. The management has reiterated plans for phased promoters pledge reduction. We value the stock on an SOTP basis by valuing the healthcare business (existing hospitals & JV) at 13x FY22E EV/EBITDA, healthcare business (new hospitals and JVs) and pharmacy business at 1.5x FY22E EV/sales. We have a target price of Rs 1800.
Valuation & Outlook: FY19 has panned out on expected lines with sustained margin expansion and improvement in ROCE, as guided by the management at the beginning of the fiscal. The management has reiterated a similar strategy, going ahead, with more focus on consolidation of existing hospitals and making new hospitals profitable. The company owns one of the best integrated business models in the healthcare space with strong management pedigree. With the proposed pharmacy reorganisation, the path is clear for an out and out unlocking in the future. We believe the stock is poised to offer a better riskreward perspective at the current level. We value the stock on an SOTP basis by valuing the healthcare business (existing hospitals & JV) at 14x FY21E EV/EBITDA, healthcare business (new hospitals and JVs) at 1.5x FY20E and pharmacy business at 1.2x FY20E EV/sales. We have a target price of 1450.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.